Retatrutide Research Overview: Identity, Documentation, and Published Context

This overview from Wellness Research Supply (WRS) addresses those procurement and documentation questions. WRS Retatrutide is supplied for laboratory / in-vitro research use only. It is not equivalent to clinical-trial material, pharmacy products, or any approved medicine. Published studies are cited here solely as scientific context.

What Retatrutide is in research identity terms

In catalog and literature nomenclature, Retatrutide is also referred to as LY3437943 (stylings such as LY-3437943 appear in product notes). Published descriptions characterize it as a triple agonist at the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. That multi-receptor identity is a research-classification fact—useful for literature mapping, assay design discussions, and material selection—not a statement of product purpose or consumer benefit.

On the WRS product page, Retatrutide is listed as a synthetic research peptide with documentation-oriented catalog specifications that laboratories commonly review before ordering. Those specifications (see the live Retatrutide product page for current details) include:

• Identity naming: Retatrutide (LY-3437943), multi-receptor research peptide (GLP-1 / GIP / glucagon receptor context in literature and catalog notes)
• Purity (catalog): >99% (HPLC), lot-confirmed on the matching Certificate of Analysis
• Molecular weight (catalog): approximately 4.8 kDa
• Form and sizes: lyophilized powder in research vials (sizes shown on the product page; currently listed in 10 mg and 30 mg presentations)
• Storage (catalog guidance): −20 °C for long-term storage; reconstituted material handled per laboratory SOPs
• Documentation: matching Certificate of Analysis for every tested batch/lot shipped

These are supply and documentation attributes for controlled laboratory use. They are not instructions for administration, and they do not imply clinical interchangeability with any investigational or commercial product used in human studies.

Published investigational context (scientific context only)

Retatrutide has been studied as an investigational agent. It is not FDA-approved. A widely cited Phase 2 clinical report is:

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. https://doi.org/10.1056/NEJMoa2301972 (PMID 37366315; ClinicalTrials.gov NCT04881760).

That paper describes Retatrutide (LY3437943) as a triple GIP/GLP-1/glucagon receptor agonist evaluated in a randomized, placebo-controlled Phase 2 program. For laboratory buyers, the relevant takeaways from the existence of this literature are limited and non-promotional:

1. Named investigational identity. The molecule has a clear research code (LY3437943) and peer-reviewed description as a triple agonist.
2. Ongoing clinical investigation context. Phase 2 clinical research has been published in a major journal; that fact situates the compound in the scientific record.
3. No catalog equivalence. Clinical-trial drug product, compounding-pharmacy preparations (where applicable in other channels), and research-catalog lyophilized peptides are different supply categories. WRS material should not be treated as a substitute for any clinical-trial lot or approved drug product.

Important compliance note for readers and publishers: Clinical outcome metrics from human trials—including any percentage body-weight or related efficacy figures—are not reasons to purchase research-catalog material and are not recycled here as product benefits. WRS cites the NEJM report only so that procurement and scientific staff can locate the primary reference when they need investigational background. Citation is not an efficacy advertisement, not a use recommendation, and not a claim that WRS products were used in that trial.

If your institution's literature review requires primary sources, use the DOI, PMID, and NCT number above. Do not rely on secondary marketing summaries when building an internal scientific file.

What documentation labs should request

When Retatrutide (or any research peptide) enters a laboratory inventory system, documentation expectations should be set before the first order—not after an assay fails a reproducibility check. At minimum, request and retain:

1. Lot-specific Certificate of Analysis (COA)

The COA should identify the compound and the lot/batch number that matches the vial label and shipping documents. Summary purity claims without a lot tie-in are weak evidence for receiving.

2. Identity method results

For peptides, mass spectrometry (observed mass / m/z consistent with expected molecular weight) is a common identity support. Confirm that identity data on the COA refers to the same lot as the purity data.

3. Purity method results

HPLC purity (often % area of the main peak) should be reported with enough method context to be interpretable—ideally including or attaching a chromatogram. Catalog statements such as ">99% (HPLC)" should be backed by the lot PDF.

4. Dates and report integrity

Prefer COAs with clear analysis or issue dates, legible figures, and consistent compound naming (Retatrutide / LY3437943 as applicable).

5. Receiving alignment

Your SOP should require a match among: vial lot, order/packing lot, and COA lot. File the PDF with the material record.

For a deeper walkthrough of HPLC, MS, and lot-matching red flags, see the companion guide: How to Evaluate a Research Peptide COA.

How WRS approaches Retatrutide supply

WRS lists Retatrutide in the research catalog with batch-aware availability and a matching Certificate of Analysis for every tested lot shipped. The intent is straightforward procurement hygiene: laboratories can review identity notes, available sizes, and COA documentation in one place, then verify the lot after delivery.

Practical paths:

• Product detail page: https://wellnessresearchsupply.com/products/retatrutide — research supply overview, catalog specifications, in-stock lot COA access on the page, and checkout. See the live page for current sizes and pricing (do not rely on archived quotes).
• COA Lookup: https://wellnessresearchsupply.com/coa — enter the lot number from your vial or order documents to retrieve the matching COA PDF. WRS describes a three-step model: batch testing (identity, purity, potency), lot tracking on the order, and on-demand COA delivery by lot number.
• Focused checkout path: OrderReta — a single-product order path for buyers who prefer a Retatrutide-focused checkout experience, still within the research-supply framing.
• U.S. fulfillment: WRS supports secure U.S. fulfillment for research orders; shipping options and timelines are shown at checkout.

Independent / third-party testing language is part of the WRS quality story; the public site does not name the external laboratory. Buyers should treat the lot COA PDF as the authoritative analytical record for the material received.

Again: WRS Retatrutide is for lawful laboratory / in-vitro research use only. It is not for human or animal consumption, diagnosis, treatment, or clinical use, and it is not presented as equivalent to investigational clinical-trial supply.

FAQ

Is WRS Retatrutide for human or veterinary use?

No. It is offered strictly for laboratory / in-vitro research use only. It is not a drug, food, or cosmetic, and it is not for human or animal use.

Is Retatrutide FDA-approved?

Retatrutide is described in the scientific literature as an investigational molecule and is not FDA-approved. Catalog research material from WRS is not an approved medicine and is not sold for therapeutic use.

Does each shipment include lot documentation?

Yes. Every unit WRS ships is from a tested batch and includes a matching Certificate of Analysis for that lot. You can open lot-specific COA access on the product page for in-stock lot(s), or look up a lot number on COA Lookup after shipment.

Are WRS peptides the same as clinical-trial Retatrutide?

No. WRS expressly states that its research material is not equivalent to clinical-trial material or pharmacy products. Published trials provide scientific context only; they do not describe the intended use of products sold here.

Where can I see current sizes and pricing?

Use the live Retatrutide product page for current vial sizes and pricing. For a Retatrutide-focused checkout path, see OrderReta.

How should my lab cite the main Phase 2 paper?

Use the NEJM citation above (Jastreboff et al., 2023; DOI 10.1056/NEJMoa2301972; PMID 37366315; NCT04881760). Keep that citation in your literature file as investigational background—not as product marketing or a use protocol.

Next steps for documented Retatrutide procurement

If Retatrutide is on your laboratory purchasing list, prioritize identity confirmation and lot paperwork alongside catalog specifications:

1. Review the live Retatrutide PDP for current sizes, pricing, and in-stock lot COA access.
2. Read How to Evaluate a Research Peptide COA before the first receiving check.
3. After delivery, verify the lot at COA Lookup.
4. If you prefer a single-product checkout path, use OrderReta.
5. Browse related documented catalog items in the full research catalog.